How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency
Volv Global is proud to be helping to organise the upcoming PCMG AI Symposium on AI in Clinical Trials, shaping
Volv Global at WODC Europe 2025 – Where Technology Meets Human Volv Global sits at the crucial intersection between technology
Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at
Volv Global will present two posters at ATS 2025, in collaboration with Takeda! Further details to come! Link to ATS:
Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out
On the occasion of international Rare Disease Day 2025, we are beyond thrilled to host the voice of patient advocate
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys
